Montelukast Ratiopharm

Montelukast, the active ingredient in Montelukast Ratiopharm, is a leukotriene receptor antagonist presented as a tablet for oral use. It is indicated for the management of asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children who require controller therapy.

GNH USA supplies Montelukast Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms. - Asthma: improves control of chronic airway obstruction and reduces exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways that occurs during or after physical activity.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often reported during treatment. - Abdominal pain: discomfort or cramping in the stomach region. - Nausea: feeling of queasiness that may lead to vomiting. - Diarrhoea: loose, watery stools occurring intermittently. - Cough: persistent dry cough without infection. - Sore throat: irritation or pain in the throat.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: mood changes, depression, anxiety or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests indicating possible liver stress. - Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement.

Before initiating therapy, clinicians should consider several safety aspects. - Assess liver function: evaluate hepatic status, especially in patients with known liver disease. - Monitor neuropsychiatric symptoms: watch for mood alterations, depression or suicidal ideation. - Use caution in severe hepatic impairment: dosage adjustment may be required. - Avoid in patients with known hypersensitivity to montelukast or any component of the formulation. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Ritonavir: can increase montelukast plasma concentrations, raising risk of side effects. - Phenobarbital: may markedly reduce montelukast exposure, diminishing therapeutic effect. - Carbamazepine: strong enzyme inducer that can lower montelukast levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR; monitor coagulation parameters. - Theophylline: possible change in plasma levels; adjust dose if needed. - Inhaled corticosteroids: may increase risk of neuropsychiatric events; observe patient closely.